Russia: +7 499 403 17 69 || Ukraine: +38 094 712 2020

Анализы на коронавирус

SARS-CoV-2 Tests available (not available for US-citizens)

Microscopic view of Coronavirus, a pathogen that attacks the respiratory tract. Analysis and test, experimentation. Sars. 3d render

The emerging Coronavirus (SARS-CoV-2 – Severe Acute Respiratory Syndrome Coronavirus 2) led to an outbreak of the respiratory disease «COVID-19» (coronavirus disease 19) in Wuhan, China, in December 2019. Similar to previous outbreaks of human coronavirus infection, SARS-CoV in 2003[1],[2] and MERS-CoV in 2012 [3], the new SARS-CoV-2 infection causes clinical symptoms such as fever, dry cough, myalgia and/or fatigue. Some patients may suffer from pain or symptoms like a stuffy or runny nose, sore throat, loss of smell (anosmia)/taste (ageusia) or diarrhoea. COVID-19 developed into a pandemic that spread rapidly in China and later worldwide.

The outbreak of this disease has forced state authorities to take drastic steps to contain the situation, including the quarantine of many millions of people across the world. However, these efforts are limited by a serious problem — the differentiation of those who are/have been infected with COVID-19 from those who do not have the infection. The clinical symptoms present in confirmed COVID-19 cases are not unique to COVID-19 since they are similar to those of other infectious viral diseases such as influenza [4]. The viral nucleic acid real-time polymerase chain reaction test is currently the standard tool for supporting clinical diagnosis of the infection [5] despite long turnaround times, the expensive equipment required and reports of false negative results for the COVID-19 RT-PCR [6].
To support efforts to contain the further spread there is an urgent need to use different test methods to swiftly identify and classify patients infected with SARS-CoV-2. This will help prevent further transmission of the virus and ensure early treatment of patients.

[1] Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953-1966.
[2] Kuiken T, Fouchier RA, Schutten M, et al. Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet. 2003;362(9380):263-270.
[3] Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814-1820
[4] Wang C, Yu H, Horby PW, et al. Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1. Clin Infect Dis. 2014;58(8):1095-1103
[5] Jin YH, Cai L, Cheng ZS, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (COVID-19) infected pneumonia (standard version). Mil Med Res. 2020;7(1):4
[6] Gallagher J. Are Coronavirus Tests Flawed? BBC News, www.bbccom/news/health-51491763. 13 Feb. 2020

ArminLabs (DE)
ArminLabs (DE)
ArminLabs (DE)

Complementary Test-Recommendations by ArminLabs
CD3+/CD56+/CD57+/CD45+ NK-Cells (Immune-Status), Zonulin and Vitamin D3.

Elderly people and patients with underlying medical conditions such as hypertension, cardiac issues or diabetes, cancer, another active infection and/or those suffering from immunosuppression are more likely to experience more severe symptoms of COVID-19 [1],[2],[3]
[1] Okba et al. medRxiv 2020.03.18.20038059; doi: 10.1101/2020.03.18.20038059; März 2020
[2] Risk of COVID-19 for patients with cancer; Hanping Wang, Li Zhang; Published:March 03, 2020
[3] The Novel Coronavirus Disease (COVID-19) Threat for Patients with Cardiovascular Disease and Cancer; Sarju Ganatra, MD, Sarah P. Hammond, MD, Anju Nohria, MD; 18 March 2020

ArminLabs therefore additionally recommend checking innate (CD3+) and natural killer cell (CD56+/CD57+) immune status, as well as other parameters related to current immune status:

ArminLabs (DE)
ArminLabs (DE)
ArminLabs (DE)